UOC
INFI

UBS O'Connor’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

UBS O'Connor’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-175,500
Closed -$2.85M – 588
2013
Q2 		$2.85M Buy
+175,500
New +$5.43M 0.05% 293

Other funds holding INFI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS O'Connor's INFI Position: Q3 2013 in Review

UBS O'Connor sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2013, closing a stake of 175,500 shares — an estimated $2.85M sold.

UBS O'Connor first reported a position in INFI in Q2 2013 and held it in 1 quarter. The position peaked at $2.85M in Q2 2013. 100 funds tracked by Wall St. Rank hold INFI as of Q3 2013.

  • UBS O'Connor reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • UBS O'Connor sold 175,500 Infinity Pharmaceuticals, Inc. shares in Q3 2013, an estimated $2.85M.
  • UBS O'Connor first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • UBS O'Connor's Infinity Pharmaceuticals, Inc. position peaked at $2.85M in Q2 2013.
  • 100 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2013.

Based on UBS O'Connor's 13F filing for Q3 2013, filed 14 Nov 2013.